Show simple item record

dc.contributor.authorSamms, RJ
dc.contributor.authorLewis, JE
dc.contributor.authorNorton, L
dc.contributor.authorStephens, FB
dc.contributor.authorGaffney, CJ
dc.contributor.authorButterfield, T
dc.contributor.authorSmith, DP
dc.contributor.authorCheng, CC
dc.contributor.authorPerfield, JW
dc.contributor.authorAdams, AC
dc.contributor.authorEbling, FJP
dc.contributor.authorTsintzas, K
dc.date.accessioned2018-02-20T08:27:17Z
dc.date.issued2017-08-04
dc.description.abstractContext: Fibroblast growth factor 21 (FGF21) secretion has been shown to respond directly to carbohydrate consumption, with glucose, fructose, and sucrose all reported to increase plasma levels of FGF21 in rodents and humans. However, carbohydrate consumption also results in secretion of insulin. Objective: The aim of this study was to examine the combined and independent effects of hyperglycemia and hyperinsulinemia on total and bioactive FGF21 in the postprandial period in humans, and determine whether this effect is attenuated in conditions of altered insulin secretion and action. Methods: Circulating glucose, insulin, total and bioactive FGF21, and fibroblast activation protein were measured in adults with and without type 2 diabetes (T2D) following an oral glucose tolerance test (OGTT), and under a series of insulin and glucose clamp conditions and following high-fat diet in healthy adults. Results: Circulating total and bioactive FGF21 levels responded acutely to OGTT, and their ratio was attenuated in T2D patients with reduced postprandial insulin response. The clamp studies revealed that insulin but not glucose accounts for the postprandial rise in FGF21. Finally, there was an attenuated rise in FGF21 in response to a high-fat dietary intervention that is known to alter insulin-stimulated substrate utilization in metabolically active tissues. Conclusions: Insulin rather than glucose per se increases total and bioactive FGF21 in the postprandial period in adult humans. Understanding the impact of T2D on bioactive FGF21 will have a significant effect upon the efficacy of therapeutic agents designed to target the FGF21 pathway.en_GB
dc.description.sponsorshipThis work was supported by the Biotechnology and Biological Sciences Research Council (UK) [grant numbers BB/M001555/1, BB/M021629/1]; and the Diabetes UK [grant number 13/0004659].en_GB
dc.identifier.citationVol. 102 (10), pp. 3806 - 3813en_GB
dc.identifier.doi10.1210/jc.2017-01257
dc.identifier.other4064265
dc.identifier.urihttp://hdl.handle.net/10871/31578
dc.language.isoenen_GB
dc.publisherOxford University Pressen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/28938434en_GB
dc.rights.embargoreasonUnder embargo until 5 August 2018 in compliance with publisher policy.en_GB
dc.rightsCopyright © 2017 Endocrine Societyen_GB
dc.subjectAdulten_GB
dc.subjectBlood Glucoseen_GB
dc.subjectDiabetes Mellitus, Type 2en_GB
dc.subjectDiet, High-Faten_GB
dc.subjectFemaleen_GB
dc.subjectFibroblast Growth Factorsen_GB
dc.subjectGlucoseen_GB
dc.subjectGlucose Clamp Techniqueen_GB
dc.subjectGlucose Tolerance Testen_GB
dc.subjectHumansen_GB
dc.subjectInsulinen_GB
dc.subjectMaleen_GB
dc.subjectMiddle Ageden_GB
dc.subjectPostprandial Perioden_GB
dc.subjectSignal Transductionen_GB
dc.subjectYoung Adulten_GB
dc.titleFGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans.en_GB
dc.typeArticleen_GB
dc.identifier.issn0021-972X
exeter.place-of-publicationUnited Statesen_GB
dc.descriptionThis is the author accepted manuscript. The final version is available from Oxford University Press via the DOI in this recorden_GB
dc.identifier.journalJournal of Clinical Endocrinology and Metabolismen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record